- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 24 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.25: 1 residues within 4Å:- Chain A: N.61
Ligand excluded by PLIPNAG.26: 5 residues within 4Å:- Chain A: N.122, T.124, N.125, V.127, K.129
Ligand excluded by PLIPNAG.27: 4 residues within 4Å:- Chain A: H.146, N.148, N.149, M.153
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain A: N.164, N.165
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain A: N.234
- Chain C: S.459, N.460, K.462
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain A: N.282
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.343, S.371, A.372
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain A: N.603
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain A: N.709, I.1130, G.1131
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain B: N.61
Ligand excluded by PLIPNAG.38: 5 residues within 4Å:- Chain B: N.122, T.124, N.125, V.127, K.129
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain B: H.146, N.148, N.149, M.153
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain B: N.164, N.165
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain A: S.459, K.462
- Chain B: N.234
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain B: N.282
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain B: N.343
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.45: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain B: N.709, I.1130, G.1131
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain C: N.61
Ligand excluded by PLIPNAG.49: 5 residues within 4Å:- Chain C: N.122, T.124, N.125, V.127, K.129
Ligand excluded by PLIPNAG.50: 4 residues within 4Å:- Chain C: H.146, N.148, N.149, M.153
Ligand excluded by PLIPNAG.51: 2 residues within 4Å:- Chain C: N.164, N.165
Ligand excluded by PLIPNAG.52: 4 residues within 4Å:- Chain B: S.459, N.460, K.462
- Chain C: N.234
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain C: N.282
Ligand excluded by PLIPNAG.54: 4 residues within 4Å:- Chain C: F.342, N.343, L.441, R.509
Ligand excluded by PLIPNAG.55: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.56: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain A: D.796
- Chain C: N.709, I.1130, G.1131
Ligand excluded by PLIP- 3 x EIC: LINOLEIC ACID(Non-covalent)
EIC.35: 17 residues within 4Å:- Chain A: C.336, P.337, F.338, F.342, Y.365, L.368, Y.369, F.374, F.377, L.387, F.392, V.395, L.513, F.515
- Chain C: R.408, T.415, G.416
17 PLIP interactions:2 interactions with chain C, 15 interactions with chain A- Hydrogen bonds: C:T.415
- Salt bridges: C:R.408
- Hydrophobic interactions: A:F.338, A:F.338, A:F.342, A:Y.365, A:Y.365, A:Y.365, A:L.368, A:F.374, A:F.377, A:L.387, A:L.387, A:F.392, A:V.395, A:L.513, A:F.515
EIC.36: 12 residues within 4Å:- Chain A: R.408, Q.409, T.415, G.416
- Chain B: F.338, I.358, Y.365, Y.369, F.374, F.377, L.387, F.392
10 PLIP interactions:7 interactions with chain B, 3 interactions with chain A- Hydrophobic interactions: B:F.338, B:I.358, B:Y.369, B:F.374, B:L.387, B:L.387, B:F.392
- Hydrogen bonds: A:T.415, A:T.415
- Salt bridges: A:R.408
EIC.47: 14 residues within 4Å:- Chain B: R.408, Q.409, G.416, K.417
- Chain C: P.337, F.338, A.363, Y.365, Y.369, F.374, F.377, L.387, F.392, L.513
13 PLIP interactions:10 interactions with chain C, 3 interactions with chain B- Hydrophobic interactions: C:F.338, C:A.363, C:Y.365, C:Y.365, C:Y.369, C:F.374, C:F.374, C:L.387, C:F.392, C:L.513
- Hydrogen bonds: B:Q.409, B:K.417
- Salt bridges: B:R.408
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ma, H. et al., Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Cell Discov (2022)
- Release Date
- 2022-03-09
- Peptides
- Spike glycoprotein: ABC
heavy chain of 2G1: DFH
light chain of 2G1: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
IH
JE
LG
MI
N
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 24 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x EIC: LINOLEIC ACID(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ma, H. et al., Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Cell Discov (2022)
- Release Date
- 2022-03-09
- Peptides
- Spike glycoprotein: ABC
heavy chain of 2G1: DFH
light chain of 2G1: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
IH
JE
LG
MI
N